Introduction
PU.1 is a member of the Ets family of transcription factors (Klemsz et al., 1990; Moreau-Gachelin et al., 1994; Wasylyk et al., 1993) and was originally identi®ed as a protein that binds to a purine-rich sequence (PU BOX) in the mouse major histocompatibility complex (MHC) class II I-Ab gene (Klemsz et al., 1990) . PU.1 expression is restricted to hematopoietic cells, predominantly the B cell and macrophage lineages, to modulate cell type-speci®c expression of genes such as the immunoglobulin (Ig) genes (Nelsen et al., 1993) and the macrophage colony-stimulating factor (M-CSF) receptor gene (Zhang et al., 1994) . Recent studies have shown that PU.1 has an important role in the hematopoietic development of these cell lineages, since disruption of the PU.1 gene in mice is lethal to animals that lack B cells and macrophages (McKercher et al., 1996; Scott et al., 1994) .
The PU.1 gene is deregulated as a consequence of proviral integration of spleen focus forming virus (SFFV) in most Friend virus-induced murine erythroleukemia (MEL) cells (Moreau-Gachelin, 1994) . It is, therefore, speculated that inappropriate expression of PU.1 in erythroid cells results in malignant transformation of the cells with an additional event such as inactivation of the p53 tumor suppressor gene (BenDavid and Bernstain, 1991) . Overexpression of PU.1 in normal bone marrow cells blocks erythroid dierentiation (Schuetze et al., 1993) , and PU.1 transgenic mice develop erythroleukemia (Moreau-Gachelin et al., 1996) .
In our previous study, we showed that overexpression of PU.1 inhibited growth and dierentiation of MEL cells and induced apoptosis when PU.1-overexpressing MEL cells were treated with a dierentiating reagent, DMSO (Yamada et al., 1997) . We further showed that down-regulation of c-myc and bcl-2 gene expression was involved in PU.1-induced apoptosis (Kihara-Negishi et al., 1998) . In this report, to understand the molecular mechanism of c-myc down-regulation by overexpression of PU.1, we carried out luciferase reporter assays using the c-myc promoter and found that PU.1 signi®cantly repressed c-myc promoter activity. The C-terminal region of PU.1 spanning amino acids 123 ± 272 was sucient for the repressor activity. PU.1-mediated repression was not attributed to sequestration of a limited amount of transcriptional coactivator such as CBP/p300 and pCAF. Rather, the repression was associated with complex formation of PU.1 with HDAC1.
Results

Overexpression of PU.1 decreases c-myc gene expression
Previously, we showed that c-myc expression was down-regulated when apoptosis was induced in MEL cells by overexpression of PU.1 along with treatment with dierentiating reagent, DMSO (Kihara-Negishi et al., 1998) . In the present study, by using RT ± PCR analysis, we examined whether overexpression of PU.1 alone could decrease c-myc expression in MEL cells. As shown in Figure 1 , c-myc expression decreased in PU.1-overexpressing MEL cells 6 h after treatment with ZnCl 2 . In contrast, no decrease was observed in mock-transfected cells under the same condition. Thus, the result demonstrates that overexpression of PU.1 alone decreases c-myc expression.
PU.1 represses c-myc promoter activity
To understand how PU.1 down-regulates c-myc expression, we investigated the eects of overexpression of PU.1 on transcriptional regulation of the c-myc gene by luciferase reporter assay. We ®rst constructed myc (SacI-SacI) Luc containing nucleotides 71483 * +517 of the mouse c-myc gene including the c-myc P1 and P2 promoters (Figure 2a) . Then, the construct was co-transfected with a PU.1 expression vector into HeLa cells which do not express PU.1 endogenously so that the eect of PU.1 was easily detected in the system. As shown in Figure 2b , addition of an expression vector containing PU.1 reduced the activity of myc (SacI-SacI) Luc in a dose-dependent manner, suggesting that PU.1 inhibits c-myc expression by modulating transcriptional regulation of the c-myc gene. Similar results were shown in MEL cells (data not shown). To determine which segment of the c-myc promoter is a target for the PU.1-mediated transcriptional repression, several deletion mutants of the promoter ( Figure 2a ) were co-transfected with a PU.1 expression vector into HeLa cells. As shown in Figure  2c , PU.1 inhibited the activities of all reporter constructs, myc (AvaI-SacI) Luc, myc (PvuII-SacI) Luc and myc (BamHI-SacI) Luc (Figure 2a ). Since the reporter of myc (BamHI-SacI) Luc contains only 44 bp of the sequence upstream of the P2 promoter, it is suggested that the target segment for PU.1-mediated transcriptional repression is the c-myc minimal promoter including the TATA box.
PU.1 inhibits several cellular and viral promoter activities
To elucidate whether the inhibition of promoter activity observed here was speci®c to the c-myc gene, the eect of PU.1 on the activities of TATA boxcontaining promoters such as the c-fos and SV40 promoters and TATA-less ones such as the b-actin and PCNA promoters were assessed by luciferase reporter assay. We co-transfected reporter constructs containing these promoters with an expression vector of PU.1 into HeLa cells. As shown in Figure 3 , PU.1 reduced the activities of all cellular and viral promoters examined to a similar extent in a dose-dependent manner. These results indicate that PU.1-mediated repression has a broad speci®city for promoters.
PU.1-mediated repression is not due to sequestration of transcriptional coactivators
The broad speci®city of the PU.1-mediated repression led us to examine the possibility that PU.1 sequestrates a limiting amount of co-activators as reported for transrepression between AP1 and steroid hormone receptors (Kamei et al., 1996) . We previously showed that a transcriptional co-activator, CREB binding protein (CBP), physically and functionally interacts with PU.1 . PU.1 also interacts with the CBP-related coactivator p300 (Yamamoto et al., unpublished observation) . Both CBP and p300 interact with a number of transcription factors to stimulate transcription by acetylating histones or transcription factors (Sartorelli et al., 1997; Puri et al., 1997; Perkins et al., 1997; Zhang et al., 1996; Eckner et al., 1994; Chakravarti et al., 1996) . Therefore, it was speculated that sequestration of a limiting amount of CBP/p300 or pCAF by an excess amount of PU.1 might be involved in PU.1-mediated transcriptional repression. To examine such a possibility, an expression vector containing CBP, p300 or pCAF was co-transfected with an expression vector for PU.1 into HeLa cells. As shown in Figure 4 , overexpression of neither CBP, p300 nor pCAF was able to relieve PU.1-mediated c-myc repression. Thus, it is unlikely that sequestration of CBP or p300 by an excess amount of PU.1 contributes to PU.1-mediated transcriptional repression.
The C-terminal aa 123 ± 272 of PU.1 are required for PU.1-mediated transcriptional repression It is known that PU.1 activates several hematopoietic cell-speci®c promoters or enhancers (Klemsz et al., 1990; Nelsen et al., 1993; Zhang et al., 1994) . To determine which domain of PU.1 is involved in repression of c-myc promoter activity, we generated Figure 1 Suppression of c-myc mRNA expression by overexpression of PU.1. PU.1 -and mock transfectants were cultured with or without 100 mM ZnCl 2 . Cytoplasmic RNA was extracted from the cells 6 h later and subjected to RT ± PCR analysis using the c-myc-speci®c primer
Complex formation of PU.1 with HDAC1 F Kihara-Negishi et al several expression plasmids of PU.1 deletion mutants ( Figure 5a ) and co-transfected them with the reporter plasmid of myc (AvaI-SacI) Luc into HeLa cells. We ®rst analysed the eects of the deletion mutants D1 ± 70, D74 ± 122 and D1 ± 100, on c-myc promoter activity. The N-terminal aa 1 ± 70 of PU.1 have been shown to encode the N-terminal TBP/RB binding domain (Hagemeier et al., 1993) , and 1 ± 122 the transactivation and CBP binding domain (Fisher et al., 1998; Yamamoto et al., 1999) . All these deletion mutants reduced c-myc promoter activity like the wild type PU.1 (Figure 5b ). These observations suggest that the N-terminal aa 1 ± 122 of PU.1 is not necessary for transcriptional repression. Then, we tested the eects of D 1 ± 164 encoding the DNA binding (Ets) domain with the C-terminal region and aa 165 ± 256 encoding the Ets domain alone, and found that these mutants did not repress the c-myc promoter activity ( Figure 5b ). These results suggest that the restricted region of PU.1 including the PEST domain is responsible for PU.1-mediated transcriptional repression.
Transrepression-active mutant of PU.1 D 1 ± 100 forms a complex with HDAC1 in vivo Recent study has established an evolutionarily conserved role for histone deacetylases (HDACs) in the mechanism of repression by transcription factors such as Mad/Max (Laherty et al., 1997) , Rb (Luo et al., 1998) , the nuclear hormone receptors (Nagy et al., 1997) , and p53 (Murphy et al., 1999) . To address the possibility that PU.1 utilizes HDACs to repress transcription, we tested the presence of a complex containing PU.1 and HDAC1 in vivo. We co- transfected an expression vector for PU.1 with that for HA-HDAC1 into 293T cells. Cell lysates from the transfected cells were then immunoprecipitated with antibody speci®c to HA and the presence of PU.1 in the immunoprecipitates was ascertained by Western blot analysis with antibody speci®c to PU.1. As shown in Figure 6a , PU.1 was found to be present in the immunoprecipitates only when both of the expression vectors were transfected. The result suggests that PU.1 forms a complex with HDAC1 in vivo. To know whether the complex formation of PU.1 with HDAC1 parallels the repressor activity of PU.1, we next examined the complex formation of the transrepression-active mutant D1 ± 100 and -negative mutant Ets (HA-165 ± 256) of PU.1 with HA-HDAC1. The deletion mutant D1 ± 100 was also eectively immunoprecipitated with HA-HDAC1 like the wild type PU.1 (Figure 6b ), while the mutant Ets (HA-165 ± 256) was not ( Figure 6c ). Thus, it is suggested that in vivo complex formation of PU.1 with HDAC1 parallels the transcriptional repressor activity of PU.1.
PU.1 also forms a complex with mSin3A
To establish whether the PU.1-HDAC1 association is direct or not, we performed a GST fusion protein assay. However, in vitro protein interaction assays indicated that PU.1 was unable to bind to HDAC1 
of three independent experiments
Complex formation of PU.1 with HDAC1 F Kihara-Negishi et al directly (data not shown). Therefore, we tested the possibility that PU.1 utilizes a corepressor protein, like mSin3A or SMRT. We co-transfected an expression vector for mSin3A with that for¯ag-PU.1,¯ag-D1 ± 100, or Ets (HA-165 ± 256) into 293T cells. Cell lysates from the transfected cells were then immunoprecipitated with antibody speci®c to¯ag or HA and the presence of mSin3A in the immunoprecipitates was ascertained by Western blot analysis with antibody speci®c to mSin3A. As shown in Figure 7a , the presence of mSin3A in the immunoprecipitates was demonstrated when the transrepression-active expression vector for¯ag-PU.1 (lane 2) or¯ag-D1 ± 100 (lane 3) was transfected with mSin3A, but not Ets (HA-165 ± 256) (lane 4). Next, we examined whether PU.1 associated directly with mSin3A using a GST fusion protein assay. In this experiment, a GST-PU.1 fusion protein, GST-D1 ± 100, or GST alone was expressed in bacteria and puri®ed by binding to glutathioneSepharose beads.
35
S-labeled mSin3A was synthesized in vitro and subsequently tested for the ability to associate with the immobilized GST fusion protein or GST alone. As shown in Figure 7b , GST-PU.1 and GST-D1 ± 100 but not GST alone were able to interact with radiolabeled mSin3A. In contrast, we found no evidence for an association between PU.1 and SMRT by in vivo immunoprecipitation assay (data not shown). These results suggest that PU.1 forms complex with mSin3A which has been related to be associated with HDAC1 .
Transrepression-active mutant of PU.1 D1-100 forms a complex with TBP in vivo Although it was suggested that PU.1 forms a complex with HDAC1 which might be involved in PU.1-mediated transcriptional repression, it was unclear how PU.1 could gain access to target promoters having no PU.1 binding sites. Since PU.1-mediated repression occurred in a variety of cellular and viral promoters, we speculated that PU.1 can associate with any basal In vitro association of PU.1 D1 ± 100 with mSin3A. Equivalent amounts of glutathione beads with immobilized and puri®ed GST PU.1, GST-D1 ± 100, or GST control were mixed with 35 S-labeled, in vitro translated mSin3A. The beads were washed, and bound proteins were eluted and analysed by NuPAGE Oncogene Complex formation of PU.1 with HDAC1 F Kihara-Negishi et al transcriptional factor to recruit HDAC1 to the promoters. TBP is an essential basic transcription factor for activation of both TATA-containing and TATA-less promoters (Pugh and Tjian, 1991) . Studies have shown that PU.1 interacts with TBP through the N-terminal 1 ± 75 by a GST fusion protein assay (Hagemeier et al., 1993) . This region was not required for PU.1-mediated repression as described above ( Figure 5 ). However, since it has been reported that p53 has two dierent domains interacting with TBP (Horikoshi et al., 1995) , we examined the possibility that the C-terminal region of PU.1 also interacts with TBP. To do this, we tested whether the transrepressionactive mutant D1 ± 100 could interact with TBP in vivo. The expression plasmid for PU.1 or mutant D1 ± 100 was co-transfected with that for¯ag-TBP into 293T cells and the immunoprecipitates with anti-¯ag antibody were ascertained to contain PU.1 by Western blot analysis with antibody speci®c to PU.1. As shown in Figure 8a , PU.1 was present in the immunoprecipitates only when both of the expression vectors were transfected (lane 2). It was not detected when only the expression vector containing PU.1 was transfected (lane 3). PU.1 D1 ± 100 was also shown to be immunoprecipitated with¯ag-TBP (lane 5). Furthermore, we tested whether PU.1 D1 ± 100 directly interacted with TBP by a similar GST fusion protein assay to that in Figure 7b . As shown in Figure 8b , GST-D1 ± 100 was able to interact with 35 S-labeled, in vitro synthesized TBP as well as GST-PU.1, while GST alone was not. Therefore, these results suggest that the transrepression-active C-terminal aa 101 ± 272 of PU.1 associates with TBP in vitro and in vivo.
Collectively, our results imply that PU.1 forms a complex with HDAC1 and TBP which may be responsible for PU.1-mediated transcriptional repression.
Discussion
In this study, we showed that overexpression of PU.1 reduces c-myc transcription by inhibiting its promoter activity. We also showed that this PU.1-mediated transcriptional repression occurs not only with the cmyc promoter but with several cellular and viral gene promoters including the c-fos, PCNA, b-actin and SV40 promoters, suggesting that PU.1 inhibits promoter activity with a broad speci®city. Activities of several reporters carrying SV40 promoter-deletion mutants and Sp-1+initiator with or without TATA sequences were also inhibited by PU.1 (data not shown). Although PU.1 transactivates a variety of promoters through its binding sites in cooperation with other transcription factors Zhang et al., 1999; Rekhtman et al., 1999) , our results suggest that PU.1 functions to repress promoter activity when promoters have no PU.1 binding sequences. Addition of an expression vector of other Ets proteins, Ets-1, Ets-2 and Fli-1 did not repress the c-myc promoter activity (data not shown), suggesting that this repression is speci®c for PU.1. Transcriptional repressors act by a variety of mechanisms including competition with activators for access to the DNA, inhibitory protein ± protein interactions with positive regulators, and recruitment of chromatin-modi®cation components to the promoter (Hanna-Rose and Hausen, 1996) . It has been reported that Ets-1 transactivates c-myc transcription at an E2F-1/Ets binding site located at position -68 of the c-myc promoter and that ETS proteins including Ets-1 and PU.1 share similar DNA binding domains (Roussel et al., 1994) . This raised the possibility that PU.1 might repress c-myc promoter activity by competition with Ets-1 at this site. However, PU.1-mediated c-myc repression was observed in myc (PvuII-SacI) Luc and myc (BamHI-SacI) Luc which do not contain the Ets binding site (Figure 2a) . Therefore, it is very unlikely that competition between Ets-1 and PU.1 at the Ets binding site of the promoter contributes to PU.1-mediated c-myc repression.
The N-terminal region of amino acids 1 ± 75 of PU.1 has been reported to interact with Rb (Hagemeier et al., 1993) and Rb represses transcription of endogenous cell cycle-related genes through recruitment of histone deacetylases (HDACs) (Luo et al., 1998; Brehm et al., 1998 ; Magnaghi-Jaulin et al., 1998) However, PU.1- F Kihara-Negishi et al mediated c-myc repression was observed in Rb-negative SAOS2 cells (data not shown) as well as in Rbinactivated HeLa cells used in this study. Furthermore, we found that the N-terminal activation domain of PU.1 was not necessary to induce transcriptional repression and the C-terminal 123 ± 272 including the PEST and Ets domains was sucient to induce the eect. Therefore, these results indicate that PU.1-mediated repression is RB-independent. Since we previously found that PU.1 interacts with transcription co-activators CBP and p300 , we speculated that PU.1-mediated transcriptional repression is due to the sequestration of these co-activators. However, the addition of CBP/ p300 did not relieve the repression (Figure 4) . Furthermore, the PU.1 mutant having a deletion in the transcriptional activation domain (aa 74 ± 122) also inhibited the c-myc promoter (Figure 2b) . Thus, the transcriptional repressor domain of PU.1 is distinct from the activation domain and it is unlikely that sequestration of co-activators is involved in PU.1-mediated transcriptional repression.
The C-terminal 123 ± 272 of PU.1 appeared to be responsible for PU.1-mediated transcriptional repression. The C-terminal region of PU.1 has been reported to interact with the leucine zipper transcription factor NF-IL6 (C/EBPd), the DNA-binding protein HMG I/Y, the multi-functional phosphatase MKP-1 and the chaperone protein HSP90 (Nagulapalli et al., 1995; Oikawa et al., 1999) . AML1, GATA-1, and Jun family transcription factors also interact with the Ets domain of PU.1 Zhang et al., 1999) . Thus, it is speculated that these factors or novel factors associating with the C-terminal aa 123 ± 272 of PU.1 are involved in the transcriptional repression demonstrated in the present study.
Histone deacetylases exist in a complex with transcriptional repressor proteins and are implicated in transcriptional repression resulting in nucleosome remodeling (Ng and Bird, 2000; Aalfs and Kingston, 2000) or inactivation of transcription factors (Juan et al., 2000) . We demonstrated here by in vivo binding assay that HDAC1 and mSin3A were recruited to PU.1 and this complex formation appeared to be associated with PU.1-mediated transcriptional repression. In support of this, PU.1 repressed the c-myc promoter activity more eciently in the presence of co-expressed HDAC1 in the luciferase reporter assay (data not shown), suggesting that PU.1 functions as a transcriptional repressor in a cooperative manner with HDAC1.
The complex formation of PU.1 with HDAC1 may have functional signi®cance in transcriptional repression. Others have reported that PU.1 repressed the activity of an IgH enhancer and c-myb promoter by binding to its own binding sequence, PU-BOX (Ross et al., 1994; Bellon et al., 1997) . Although we here demonstrated PU.1-mediated repression of the promoters without PU-BOX, our results raise the possibility that complex formation of PU.1 with HDAC1 may be also involved in PU-BOX-mediated repression.
We have previously reported that PU.1 interacts with the coactivator CBP and the interaction has been implicated in transactivation . Thus, PU.1 may function as both a positive and a negative regulator depending upon the cofactor. In this context, it is well known that unliganded nuclear hormone receptors act as transcriptional repressors by recruiting HDACs but with their ligands they act as transcriptional activators by recruiting CBP/p300 (Baniahmad et al., 1993 (Baniahmad et al., , 1995 . Additionally, since CBP has been shown to have histone acetylase activity and to regulate some transcription factors by acetylation (Sakaguchi et al., 1998; Giaccia and Kastan, 1998) , the transcriptional regulatory activity of PU.1 might be modi®ed and directed by acetylation by CBP or deacetylation by HDACs.
We have mapped the domain required for complex formation of PU.1 with HDAC1 to the C-terminal aa 123 ± 272 of PU.1. We demonstrated that the Cterminal region of PU.1 is also associated with TBP in vitro and in vivo. Other investigators reported that the N-terminal aa 1 ± 75 of PU.1 interacts with TBP (Hagemeier et al., 1993) . Thus, PU.1 appears to interact with TBP via its N-and/or C-terminal regions.
We previously demonstrated that overexpression of PU.1 inhibits dierentiation in MEL cells and inhibition of b-globin gene expression also occurred on overexpression of the mutant form of PU.1 deleted of the activation domain (aa 74 ± 122) (Yamada et al., 1997) . The domain responsible for the dierentiation inhibition contains the region (aa 123 ± 272) required for PU.1-mediated transcriptional repression shown in the present study. Furthermore, it has been reported that the hematopoietic-speci®c DNA binding protein for sites in b-globin intervening sequence 2 is identical to PU.1 (Galson et al., 1993) . These results raise the possibility that repressor activity of PU.1 is involved in the dierentiation inhibition of MEL cells.
In summary, the results of this study, taken together with our previous ®ndings , suggest that PU.1 acts as a transcriptional activator by recruiting CBP/p300 and also as a transcriptional repressor by recruiting HDACs. It is important to elucidate the cellular conditions causing PU.1 to interact with CBP/p300 or with HDACs. The answer to these questions will help to clarify the physiological signi®cance of PU.1 in hematopoietic cell growth and dierentiation.
Materials and methods
Cell lines and cell culture
HeLa and 293T cells were maintained in DMEM supplemented with 10% fetal bovine serum. PU.1-and mock transfected cells were established from MEL-B8/3 (mouse erythroleukemia) cells by introduction of a zinc-inducible expression plasmid containing the PU.1 gene and an empty vector, respectively (Yamada et al., 1997) . These transfectants were maintained in RPMI-1640 medium supplemented with Oncogene Complex formation of PU.1 with HDAC1 F Kihara-Negishi et al 10% fetal bovine serum. Cells were serially maintained in 5% CO 2 at 378C until use.
RT ± PCR analysis PU.1-and mock transfected cells were cultured with or without 100 mM ZnCl 2 for 6 h. RNA was extracted from the cells and RT ± PCR analysis was performed as we described previously (Kihara-Negishi et al., 1998) . The c-myc PCR primers used were 5'-GGGCCAGCCCTGAGCCCCTAG-TGC-3' and 3'-CCAGCCTCAGCCCGAGTAGAGGTA-5'.
Plasmids
A SacI-SacI (71483*+517), AvaI-SacI (7138*+517), PvuII-SacI (+24*+517) or BamHI-SacI (+116*+517) fragment upstream of the mouse c-myc gene was inserted into pGL3 plasmid (Promega) to construct myc (SacI-SacI) Luc, myc (AvaI-SacI) Luc, myc (PvuII-SacI) Luc, or myc (BamHISacI) Luc, respectively. The expression vectors of PU.1 and deletion mutants of PU.1 were constructed by inserting each full-length or deleted cDNA into pcDNA series vectors (Invitrogen). For construction of¯ag-PU.1 and¯ag-D1-100, pCMV-Tag2 (STRATAGENE) was used. The Ets (HA-165 ± 256) expression vector was constructed by inserting the sequence of HA Tag and PU.1 Ets domain into pcDNA (Invitrogen). The expression plasmids for HA-HDAC1 and mSin3A were kindly provided by Dr I Kitabayashi, National Cancer Center, Japan.
